Neurocrine Biosciences
NBIX
#1490
Rank
C$20.63 B
Marketcap
C$203.03
Share price
0.84%
Change (1 day)
4.72%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): C$9.82

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is C$10.05. In 2025 the company made an earnings per share (EPS) of C$6.87 an increase over its 2024 EPS that were of C$4.82.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$9.8242.89%
2025C$6.8742.6%
2024C$4.8233.07%
2023C$3.6257.76%
2022C$2.2969.47%
2021C$1.35-78.21%
2020C$6.21990%
2019C$0.5781.82%
2018C$0.31-113.5%
2017C-$2.320.62%
2016C-$2.3157.28%
2015C-$1.4725.61%
2014C-$1.1718.84%
2013C-$0.98-1085.71%
2012C$0.09978

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
C$1.08-89.22%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
C$5.09-49.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
C$42.60 323.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
C$1.07-89.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
C-$2.89-128.79%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
C$6.88-31.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
C-$10.76-207.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
C$2.67-73.39%๐Ÿ‡ฌ๐Ÿ‡ง UK